Tackling the translational challenges of multi-omics research in the realm of European personalised medicine: A workshop report

Personalised medicine (PM) presents a great opportunity to improve the future of individualised healthcare. Recent advances in -omics technologies have led to unprecedented efforts characterising the biology and molecular mechanisms that underlie the development and progression of a wide array of co...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in molecular biosciences Vol. 9; p. 974799
Main Authors Oldoni, Emanuela, Saunders, Gary, Bietrix, Florence, Garcia Bermejo, Maria Laura, Niehues, Anna, ’t Hoen, Peter A. C., Nordlund, Jessica, Hajduch, Marian, Scherer, Andreas, Kivinen, Katja, Pitkänen, Esa, Mäkela, Tomi Pekka, Gut, Ivo, Scollen, Serena, Kozera, Łukasz, Esteller, Manel, Shi, Leming, Ussi, Anton, Andreu, Antonio L., van Gool, Alain J.
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 13.10.2022
Subjects
bottlenecks in health data
EU initiatives
Molecular Biosciences
multi-omics
personalised medicine
research infrastructures
translational medicine
Online AccessGet full text

Cover

More Information
Summary:Personalised medicine (PM) presents a great opportunity to improve the future of individualised healthcare. Recent advances in -omics technologies have led to unprecedented efforts characterising the biology and molecular mechanisms that underlie the development and progression of a wide array of complex human diseases, supporting further development of PM. This article reflects the outcome of the 2021 EATRIS-Plus Multi-omics Stakeholder Group workshop organised to 1) outline a global overview of common promises and challenges that key European stakeholders are facing in the field of multi-omics research, 2) assess the potential of new technologies, such as artificial intelligence (AI), and 3) establish an initial dialogue between key initiatives in this space. Our focus is on the alignment of agendas of European initiatives in multi-omics research and the centrality of patients in designing solutions that have the potential to advance PM in long-term healthcare strategies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Marie-Pier Scott-Boyer, L’Institut de Radiobiologie Cellulaire et Moléculaire, France
ORCID: Emanuela Oldoni, orcid.org/0000-0002-9105-2601; Gary Saunders, orcid.org/0000-0002-7468-0008; Florence Bietrix, orcid.org/0000-0002-0499-9435; Andreas Scherer, orcid.org/0000-0002-4254-7122; Maria Laura Garcia Bermejo, orcid.org/0000-0002-8167-2276; Peter-Bram ’t Hoen, orcid.org/0000-0003-4450; Anna Niehues, orcid.org/0000-0002-9839-5439; Jessica Nordlund, orcid.org/0000-0001-8699-9959; Marian Hajduch, orcid.org/0000-0002-4834-908X; Katja Kivinen, orcid.org/0000-0002-1135-7625; Esa Pitkänen, orcid.org/0000-0002-9818-6370; Tomi Pekka Mäkela, orcid.org/0000-0002-4869-8044; Ivo Gut, orcid.org/0000-0001-7219-632X; Serena Scollen, orcid.org/0000-0002-9311-1337; Łukasz Kozera, orcid.org/0000-0002-9015-4518; Manel Esteller: orcid.org/0000-0003-4490-6093; Leming Shi, orcid.org/0000-0002-2981-4150; Anton Ussi, orcid.org/0000-0001-7342-7062; Antonio L Andreu, orcid.org/0000-0002-3936-3234; Alain van Gool, orcid.org/0000-0003-0010-5286
This article was submitted to Metabolomics, a section of the journal Frontiers in Frontiers in Molecular Biosciences
Edited by: Ornella Cominetti, Nestlé Research Center, Switzerland
ISSN:2296-889X
2296-889X
DOI:10.3389/fmolb.2022.974799